Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Improved RCC survival attributed to better therapy, not earlier diagnosis

Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023

Key clinical point: Improved renal cell carcinoma survival appears to be attributable to improvements in therapy rather than increased diagnosis of early-stage disease.

Major finding: 5-year survival increased from 9.8% in 2004 to 13.2% in 2010 for patients with distant metastatic disease.

Study details: Retrospective analysis of data from the National Cancer Database on 262,597 patients diagnosed with RCC from 2004 through 2015.

Disclosures: No study funding source was reported. Dr. Patel and coauthors reported having no conflicts of interest to disclose.

Read the article.

Citation:

Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023

This Week's Must Reads

Healthcare.gov open enrollment picks up in Week 2, Weekly enrollment snapshot on CMS.gov

Trump administration takes contradictory actions on ACA, A press statement issued on CMS.gov.

Doctors raise concerns about administration's Part B drug plan, A CMS Fact Sheet on the ANPRM International Pricing Index Model for Medicare Part B Drugs

Guideline authors inconsistently disclose conflicts, Combs T et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.4730. Khan R et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.5106

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018